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O01 GENETIC RISK FACTORS ASSOCIATED WITH
INCREASED RISK OF UVEITIS IN PATIENTS WITH JUVENILE
IDIOPATHIC ARTHRITIS
Melissa Tordoff1, Samantha L. Smith1, Elena Lopez-Isac1,
Andrew Morris1, Stephen Eyre1, Wendy Thomson1 and John Bowes1
1Centre for Genetics and Genomics Versus Arthritis, The University of
Manchester, Manchester, UNITED KINGDOM
Background/Aims
Juvenile idiopathic arthritis (JIA) is a childhood-onset rheumatic
disease, which is associated with increased risk of uveitis.
Approximately 80% of childhood chronic anterior uveitis cases are
JIA-associated (JIAU), where it is considered a serious complication
with the potential to lead to permanent blindness. Studies have
reported associations of increased risk of JIAU to genetic variation
within human leukocyte antigen (HLA) genes, in particular amino acid
positions of HLA-DRB1. Here we report the results of the largest fine-
mapping study of HLA genes in JIAU to date.
Methods
Genotyping was performed using Illumina Infinium CoreExome and
Infinium OnmiExpress arrays. Samples were excluded with a call rate
<0.98, discrepancy between genetically inferred sex and database
records, inferred relatedness (Identity-by-decent), or ancestral outlier
based on principal component analysis (PCA). SNPs were excluded
with a call rate <0.98 or a minor allele frequency (MAF) <0.01. HLA
alleles, amino acids, and SNPs were imputed using SNP2HLA.
Analysis was performed on markers with an information score >0.9
and MAF > 0.01 using logistic regression, or omnibus test for multi-
allelic markers, including 3 PCs as covariates. Independent effects
were identified using forward stepwise logistic regression by inclusion
of previously identified variants as covariates.
Results
We analysed 7,425 markers across the HLA region in 450 JIAU cases
and 2,024 JIA cases. We defined study-wide significance at a
Bonferroni corrected threshold of 6.7x10-6. The most significant
association was at amino acid position 13 of DRB1 (p-value ¼
3.0x10-30) where the presence of serine (OR 1.7, 95% CI 1.4-1.9) or
glycine (OR 2.0, 95% CI 1.6-2.5) were associated with increased risk of
uveitis. Conditioning on DRB1 position 13, found a further association
to amino acid position 67 of DRB1 (p-value ¼ 2.4x10-6, unconditioned
p-value ¼ 3.2x10-23). The presence of isoleucine (OR 1.5, 95% CI 1.2-
1.9) and phenylalanine (OR 1.8 95%, CI 1.4-2.2) at position 67 were
associated with increased risk. No further study-wide associations
were found at DRB1. Conditioning on all HLA-DRB1 alleles identified
an independent effect at amino acid position 69 in DPB1 (p-value ¼
5.3x10-7, unconditioned p-value ¼ 1.1x10-10). The presence of
glutamic acid was associated with increased risk (OR 1.7, 95% CI
1.4-2.0).
Conclusion
This is the largest genetic study of HLA regions in JIAU and further
resolves the genetic risk factors in this key susceptibility region. The
analysis in this study has independently validated the association
signal at position 13 of HLA-DRB1 (highly correlated with position 11)
that had been reported in a previous study. Conditional analysis of
HLA-DRB1 revealed a novel secondary association signal at DRB1 to
amino acid position 67. Conditional analysis on all DRB1 alleles
confirmed association to position 69 of HLA-DPB1 where previous
reports of this signal had been only modestly associated.
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O02 LOW BIRTHWEIGHT IS ASSOCIATED WITH
DECREASED GRIP STRENGTH AND REDUCED LEG MUSCLE
MASS IN MIDDLE AGE: FINDINGS FROM THE UK BIOBANK
IMAGING ENHANCEMENT
Elizabeth M. Curtis1, Stefania D’Angelo1, Shanze Ashai1,
Kate Ward1, Zahra Raisi-Estbragh2, Steffen Petersen2,
Cyrus Cooper1 and Nicholas C. Harvey1
1University of Southampton, MRC Lifecourse Epidemiology Unit,
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Barts Biomedical Research Centre, Queen Mary University of
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Background/Aims
Low birthweight has been shown to be associated with poorer
musculoskeletal health in later life in a variety of epidemiological
studies. We investigated relationships between birthweight and
magnetic resonance imaging (MRI) measures of muscle volume, and
between birthweight and measures of grip strength in UK Biobank.
Methods
UK Biobank is a large prospective cohort of men and women aged
40-69 years, including a detailed baseline assessment in which
birthweight was collected by self-report. A subset of participants
underwent MRI examination with the dual-echo Dixon Vibe protocol,
from neck to knees. Automated body composition analysis was
performed using the AMRA ProfilerTM system, to segment and quantify
total thigh muscle volume. Grip strength was assessed using a Jamar
hydraulic hand dynamometer. Associations between birthweight, and
thigh muscle volume or grip strength (expressed as Fisher-Yates z-
scores) were investigated using multivariate linear regression analysis.
This study was conducted under generic ethics approval (NRES:11/
NW/0382).
Results
13,048 participants [5,508 men, mean (SD) age 61.9 (7.6) years and
7,540 women, age 60.9 (7.2) years] were able to recall their birthweight
and underwent MRI body composition analysis or had a measurement
of grip strength. In both men and women, higher birthweight was
associated with greater thigh muscle volume (adjusted for age and
body mass index (BMI)): men, b (95% CI): 0.23 (0.16,0.30) SD/kg,
p<0.001; women, b (95% CI): 0.28 (0.22,0.35) SD/kg, p<0.001.
Higher birthweight was also associated with higher grip strength
(adjusted for age and height); men, b (95% CI): 0.09 (0.06,0.13) SD/kg,
p<0.001; women, b (95% CI): 0.06 (0.02,0.09) SD/kg, p¼ 0.001. All
associations were robust to additional adjustment for current smoking
and physical activity.
Conclusion
Birthweight was positively associated with MRI measures of thigh
muscle volume and grip strength in a population of middle-aged UK
adults. These findings provide novel evidence in support of the
developmental programming hypothesis and suggest that interven-
tions to optimise birthweight may help to prevent sarcopenia and
reduce the risk of falls in future generations. (Project 3593)
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O03 PREVALENCE OF FRAGILITY FRACTURES AND
MEDICATION PRESCRIPTION FOR OSTEOPOROSIS IN
PATIENTS WITH POLYMYALGIA RHEUMATICA: RESULTS
FROM THE PMR COHORT STUDY
Balamrit Singh Sokhal1, Samantha L. Hider2,3, Zoe Paskins2,3,
Christian D. Mallen2 and Sara Muller2
1Keele University, Medical School, Newcastle Under-Lyme, UNITED
KINGDOM, 2Primary Care Centre Versus Arthritis, School of
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UNITED KINGDOM
Background/Aims
Polymyalgia rheumatica (PMR) is one of the commonest indications for
long term glucocorticoid (GC) use, leading to an increased risk of
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osteoporosis and fragility fractures. Clinical guidelines recommend
prescribing medication including vitamin D, calcium and anti-resorp-
tives, such as bisphosphonates. The aim of this study was to examine
the association of reported falls and prescriptions of medications for
osteoporosis with future fragility fractures in a cohort of people with
PMR.
Methods
652 people with an incident diagnosis of PMR responded to a baseline
survey between June 2012 and June 2014. This included data on
general health, sociodemographics, history of falls and medication.
Data on fractures and prescriptions were collected at 12 and 24
months. Fragility fractures were defined as fractures of the hip, wrist or
spine. Logistic regression models were used to assess the association
between baseline characteristics and fractures at 12 and 24 months.
Analysis was conducted unadjusted and adjusted for age, gender,
reported medication use and falls history.
Results
112 (17.2%) baseline respondents reported a previous fragility
fracture. 60 (83.3%) of the 72 respondents who reported a fragility
fracture between baseline and month 12 also reported a fragility
fracture at baseline. 49 (79.1%) of the 60 respondents who reported a
fragility fracture at between the month 12 and 24 also reported a
fragility fracture at baseline. Falls before baseline was the most
significant predictor of fragility fracture at 12 (OR 2.35 95% CI 1.35-
4.12) and 24 (OR 1.91 95% CI 1.05-3.49) months. Fewer than 50% of
respondents were ever prescribed treatment for osteoporosis. Being
prescribed treatment for osteoporosis was associated with a reduced
incidence of fragility fractures at 24 months (adjusted OR 0.28 95% CI
0.10-0.80), but an increased incidence at 12 months (adjusted OR 2.10
95% CI (1.3-3.48). Calcium and vitamin D prescription, gender and age
were not significantly associated with fracture outcome.
Conclusion
Despite guidelines, fewer than 50% of patients were prescribed
medications for osteoporosis. This data highlights the risks of fractures
in PMR patients who have experienced previous falls. Over a period of
two years, medication for osteoporosis was significantly protective,
hence more needs to be done to encourage adherence to guidelines.
Further studies need to address reasons for non-adherence to
guidelines and the effects of long-term treatment.
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O04 PATIENT ENGAGEMENT WITH REMOTELY DELIVERED
COGNITIVE-BEHAVIOURAL AND GRADED-EXERCISE
INTERVENTIONS TO LESSEN THE IMPACT OF FATIGUE IN
INFLAMMATORY RHEUMATIC DISEASES: A QUALITATIVE
EVALUATION
Sarah E. Bennett1,2, Emma Dures1,2, Celia Almeida1,2, Eva-
Maria Bachmair3, Karina Lovell4, Lorna Paul5, Alison Wearden4, Gary
J. Macfarlane3, Neil Basu6 and The LIFT study team.
1Department of Nursing and Midwifery, The University of the West of
England, Bristol, UNITED KINGDOM, 2Academic Rheumatology,
Bristol Royal Infirmary, Bristol, UNITED KINGDOM, 3Aberdeen
Centre for Arthritis and Musculoskeletal Health (Epidemiology
Group), University of Aberdeen, Aberdeen, UNITED KINGDOM,
4School of Health Sciences, University of Manchester, Manchester,
UNITED KINGDOM, 5School of Health and Life Science, Glasgow
Caledonian University, Glasgow, UNITED KINGDOM, 6Institute of
Infection, Immunity and Inflammation, University of Glasgow,
Glasgow, UNITED KINGDOM
Background/Aims
Fatigue is a substantial, disabling symptom of inflammatory rheumatic
diseases (IRDs). LIFT (Lessening the Impact of Fatigue in inflammatory
rheumatic diseases: a randomised Trial) is a multi-centre three-arm
randomised trial using remotely delivered cognitive-behavioral
approach (CBA) and personalised exercise programme (PEP) inter-
ventions, compared to normal care alone, with the aim to lessen the
impact of fatigue in patients with IRDs. Most sessions were delivered
by telephone. This nested qualitative study explored patients’
experiences of taking part in the interventions.
Methods
A subgroup of patients who had completed follow-up after the LIFT
trial took part in semi-structured telephone interviews to discuss their
views and experiences of the interventions and subsequent impact on
their lives.
Results
Participants were purposively sampled from six UK research sites to
include variation in gender, age and IRDs. A total of 47 participants (33
women, 14 men) from the PEP (n¼ 22) and CBA (n¼ 25) arms took
part. SB conducted an inductive thematic analysis of the data set. ED,
CA, AW and KL reviewed a sub-set of the data. Five main themes were
agreed after group discussion: There is no miracle cure, but LIFT is a
way to manage fatigue: participants had disabling fatigue, with
substantial impact on their work and social lives. Many were keen to
understand the link between their IRD and fatigue. Participants
reflected that LIFT could not offer a miracle cure, but most felt that
they were better able to cope with their fatigue after taking part.
Building a therapeutic relationship: participants reported feeling
validated by LIFT therapists who understood the impact of IRD-
fatigue. They valued the continuity of interacting with the same
therapist throughout the intervention.
The advantages of structure, self-monitoring and being accountable:
many participants liked the structured format of the interventions and
the inclusion of techniques such as goal setting because self-
monitoring and being accountable to the therapist were helpful.
Some felt guilty if they did not meet their goals but used this as an
incentive to set more realistic objectives.
A new toolbox: many participants described feeling more confident
and empowered after the interventions, with a new ‘toolbox’ of coping
mechanisms; more motivated to socialise, exercise and better able to
pace activity. PEP participants who were physically active prior to LIFT
saw less benefit.
LIFT going forward - a tailored remotely delivered programme:
participants’ ideas included follow-up sessions at six and twelve
months; the option for video calling; and group-based sessions to
boost engagement and receive social support from other patients with
fatigue.
Conclusion
Many patients engaged with the LIFT interventions and reported
benefits of taking part. This suggests an important role for the remote
delivery of fatigue self-management as services respond and adapt to
the current pandemic.
Disclosure
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O05 JUVENILE IDIOPATHIC ARTHRITIS IS CORE BUSINESS
IN ADULT RHEUMATOLOGY: THE CASE FOR SPECIALIST
SERVICES
Rebecca J. Nock1, James R. Maxwell2 and Rachel S. Tattersall2
1The Medical School, The University of Sheffield, Sheffield, UNITED
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Background/Aims
Juvenile idiopathic arthritis (JIA) is a heterogenous, childhood-onset
condition persisting into adulthood in over 50% of people. Recognition
of JIA-specific features is poor in adult services, there are no validated
disease activity scores for adults with JIA and specialist adult JIA
clinics are rare; this leads to under-treatment of adults with JIA.
Sheffield Teaching Hospitals (STH) has a mature transition service and
well-established young adult clinic (YAC) for 16-25 year olds and older
adults with JIA. Here, we evaluate the proportion of our adult
rheumatology workload attributable to JIA, the prevalence of JIA
subtypes and therapies utilised.
Methods
Outpatient attendances in STH rheumatology are coded by diagnosis.
The evaluation period was 1.12.2018 to 27.2.2020. We evaluated the
number and characteristics of patients in the JIA cohort, producing a
database from coded diagnoses and patient records, and analysed
this using Microsoft Excel. Local permission was granted.
Results
11,520 patients were seen in adult rheumatology in the evaluation
period; 9,422 had a coded diagnosis of which 4,915 (52%) had
inflammatory arthritis (IA). Assuming a proportional number of the
2,098 non-coded patients had IA (1,090), the adult IA cohort is
estimated at 6,005. 304 patients (aged 17-72) with JIA were seen in
adult rheumatology, accounting for 5% of the adult IA cohort. 280
(92%) were in the YAC, and 24 (8%) in general rheumatology. 31 (10%)
patients had evidence of uveitis. The commonest subtypes of JIA
were: 75 polyarticular (25%), 38 enthesitis related (13%) and 37
extended oligoarticular (12%). 64 (21%) patients had no subtype
specified. Of the 233 (77%) JIA patients ever treated with methotrex-
ate, 132 (57%) had discontinued due to inefficacy or adverse effects.
175 (58%) patients were on biologic treatment: the commonest
therapies were adalimumab (40%, 70 patients) and etanercept (27%,
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